US FDA approves first drug shown to reduce risk of HIV infection | Society | guardian.co.uk.
What happens with the anti-infectives which are used for PREVENTION, instead of treating infections?
Resistance abounds.
The FDA has approved the use of Truvada, an antiretroviral agent with two ingredients, emtricitabine (nucleoside reverse transcriptase inhibitor) and tenofovir, (nucleotide reverse transcriptase inhibitor). This is now recommended for use in a non-infected partner who decides to have sexual contact with an HIV infected partner. The protection rate in the most favorable African study is 75%. Other studies done in the U.S. show results which are not nearly that good. Participants in the Truvada HIV prevention studies were encouraged to also use condoms.
Hope that extra special sex is worth $14,000 per year in the U.S., the still present risk of HIV, the risk of kidney damage, as well as the risk of making HIV strains more resistant to two more drugs, and the combo cocktails which contain them.
Pharmer chalks this FDA decision up with the scores of other irrational choices to misuse drugs without consideration of the present and long term drawbacks.
